Jim Cramer reveals how the Fed's rose-colored glasses could impact your money. » Read More
By: Thomas Franck
Popular marijuana stocks fell across the board Wednesday even as Canada became the largest country to legalize the recreational use of cannabis. » Read More |
Pfizer's offering early retirement ahead of layoffs early next year, it announced internally to employees Tuesday. The company, which currently employs more than 90,000 workers, didn't say how many people it plans to cut. » Read More |
By: Elizabeth Gurdus
Jim Cramer breaks down how Netflix's recent quarter proved the FANG haters wrong. » Read More |
Jim Cramer continues his "power rankings" with the health-care sector. His stock picks include a hospital operator, an animal health play and a medical robot maker.
Pharmaceuticals have been fueling J&J's growth while its consumer and medical device businesses have lagged.
CVS is trying to become a disruptive force itself with its roughly $69 billion acquisition of health insurer Aetna.
Marijuana stocks rally after one of the largest Canadian cannabis companies announces it has agreed to acquire a U.S.-based hemp company.
The announcement comes just hours before Health and Human Services Secretary Alex Azar is expected to introduce a proposal that would require drugmakers to include the list price in their direct-to-consumer advertisements.
The proposal is slated to be introduced next week, Politico reported, citing four people with knowledge of the plan. It's a key piece of President Donald Trump's blueprint to lower drug prices, which the administration unveiled in May.
Antibiotic-resistance infections are on the rise globally, resulting in a major health crisis. SciBac, a Silicon Valley start-up backed by Peter Thiel's Breakout Labs, has invented a microbiome pill to tackle superbugs.
Jim Cramer details Eli Lilly's miraculous rally and how it went from loathed to loved in a matter of months.
Guardant Health CEO Helmy Eltoukhy told CNBC on Thursday the company's liquid biopsy, Guardant360, is a "big game changer" when it comes to the detection of cancer.
Testosterone replacement therapy is gaining wider use, but there are potential health risks. These include heart attack and stroke in men over 65 and infertility in young men.
Powerful PCSK9 inhibitors were supposed to revolutionize care for cardiac patients. But insurers and other payers balked at sky-high prices, The New York Times reports.
More and more investors are betting the fish on your plate will one day come from stem cells grown in bioreactors, instead of the ocean.
China's health-care system is cracking under the weight of a population of more than one billion people – especially when many patients run to hospitals for a fever, the New York Times reports.
Pfizer Chief Executive Officer Ian Read will hand over the reins of the largest U.S. drugmaker to veteran insider Albert Bourla in January, after eight years at the helm, in the backdrop of increased scrutiny over drug pricing.
Allergies are on the rise and researchers are trying new methods to help combat potentially life threatening reactions.
Flu caused a record number of more than 80,000 deaths and 900,000 hospitalizations in the United States last year.
Get the best of CNBC in your inbox
Data also provided by 
